172 related articles for article (PubMed ID: 6165457)
1. Combined interferon--antimetabolite therapy of murine L1210 leukemia.
Slater LM; Wetzel MW; Cesario T
Cancer; 1981 Jul; 48(1):5-9. PubMed ID: 6165457
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
Roberts D; Hilliard SL
Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
[No Abstract] [Full Text] [Related]
3. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
Schmid FA; Hutchison DJ
Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
[No Abstract] [Full Text] [Related]
4. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
Warzocha K; Robak T
Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of combinations of interferons and cytotoxic drugs in murine tumor models in vivo.
Harrison SD; Stevens JJ; Waud WR; Dykes DJ; Schmid SM; Griswold DP
J Biol Response Mod; 1990 Aug; 9(4):395-400. PubMed ID: 2118561
[TBL] [Abstract][Full Text] [Related]
6. [Effects of combination chemotherapy of MCNU with various anti-cancer agents].
Machida S; Ito Y; Hoshino A
Gan To Kagaku Ryoho; 1985 Feb; 12(2):298-302. PubMed ID: 3918506
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents.
Glae GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
J Natl Cancer Inst; 1976 Dec; 57(6):1363-6. PubMed ID: 187805
[TBL] [Abstract][Full Text] [Related]
8. Single versus combination chemotherapy of L1210 leukemia.
Koza I; Balázová E; Ujházy V
Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
[TBL] [Abstract][Full Text] [Related]
9. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin.
Zagozdzon R; Gołab J; Stokłosa T; Giermasz A; Nowicka D; Feleszko W; Lasek W; Jakóbisiak M
Int J Cancer; 1998 Aug; 77(5):720-7. PubMed ID: 9688305
[TBL] [Abstract][Full Text] [Related]
10. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
11. [Effect of combination chemotherapy of nitrosourea MCNU with various anti-tumor agents].
Ninomiya K; Sekido S; Araki T
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1315-23. PubMed ID: 6428326
[TBL] [Abstract][Full Text] [Related]
12. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
Góra-Tybor J; Robak T; Warzocha K; Grieb P
Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
[TBL] [Abstract][Full Text] [Related]
13. Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate.
Mabel JA; Wodinsky I
Cancer; 1983 Feb; 51(4):600-5. PubMed ID: 6401590
[TBL] [Abstract][Full Text] [Related]
14. THE EFFECT OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE HYDROCHLORIDE ON MURINE NEOPLASMS.
EVANS JS; MUSSER EA; BOSTWICK L; MENGEL GD
Cancer Res; 1964 Aug; 24():1285-93. PubMed ID: 14216163
[No Abstract] [Full Text] [Related]
15. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
Kim K; Blechman WJ; Riddle VG; Pardee AB
Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
[TBL] [Abstract][Full Text] [Related]
16. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Avery TL; Roberts D
Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
[TBL] [Abstract][Full Text] [Related]
17. [Experimental combination chemotherapy of YNK01, a novel analog of cytarabine, with other antitumor agents].
Uchida T; Nagahata T; Arakawa M; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Jul; 17(7):1351-6. PubMed ID: 2114829
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia.
Sackmann-Muriel F; Svarch E; Eppinger-Helft M; Braier JL; Pavlovsky S; Guman L; Vergara B; Ponzinibbio C; Failace R; Garay GE; Bugnard E; Ojeda FG; De Bellis R; de Sijvarger SR; Saslavsky J
Cancer; 1978 Oct; 42(4):1730-40. PubMed ID: 101296
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of adriamycin combined with methotrexate against L1210 leukemia in mice.
Valeriote F; Vietti T; Coulter D
J Natl Cancer Inst; 1980 Apr; 64(4):801-5. PubMed ID: 6928994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
